Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, 110029, India.
Department of Radiotherapy and Oncology, All India Institute of Medical Sciences, New Delhi, India.
Virol J. 2024 Sep 20;21(1):224. doi: 10.1186/s12985-024-02473-0.
Nasopharyngeal carcinoma (NPC) is often diagnosed at a very advanced stage due to its location and non-specific initial symptoms. Moreover, no clinically useful serological marker has been established so far for early detection of NPC. In this study, we have investigated the clinical significance of plasma Epstein-Barr virus DNA load along with interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) levels to evaluate if these three all together can be useful as a strong serological marker for early detection and prediction of treatment response in patients with NPC. Plasma EBV DNA load, IL-6 level, VEGF expressions were measured in 24 patients with NPC at presentation and various time points during and after treatment. There was a positive correlation between high plasma EBV DNA load with higher IL-6 and VEGF expression, which was closely associated with therapeutic response as well. Persistent or recurrent plasma EBV load with higher IL-6 and VEGF levels can potentially predict disease progression and may be useful to select patients for additional therapy and longer follow-up.
鼻咽癌（NPC）由于其位置和非特异性的初始症状，通常在非常晚期才被诊断出来。此外，迄今为止，尚未建立用于 NPC 早期检测的临床有用的血清标志物。在这项研究中，我们研究了血浆 Epstein-Barr 病毒 DNA 载量以及白细胞介素-6（IL-6）和血管内皮生长因子（VEGF）水平的临床意义，以评估这三者是否可以作为 NPC 患者早期检测和治疗反应预测的有力血清标志物。在就诊时以及治疗期间和之后的各个时间点，对 24 例 NPC 患者的血浆 EBV DNA 载量、IL-6 水平和 VEGF 表达进行了测量。高血浆 EBV DNA 载量与更高的 IL-6 和 VEGF 表达呈正相关，这与治疗反应密切相关。持续或复发的血浆 EBV 载量以及更高的 IL-6 和 VEGF 水平可能预示疾病进展，可能有助于选择患者进行额外的治疗和更长时间的随访。
